15,438 Shares in Boston Scientific Corporation $BSX Bought by Capital Asset Advisory Services LLC

Capital Asset Advisory Services LLC purchased a new stake in Boston Scientific Corporation (NYSE:BSX) in the first quarter, HoldingsChannel reports. The fund purchased 15,438 shares of the medical equipment provider’s stock, valued at approximately $942,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of BSX. Essex Financial Services Inc. raised its position in shares of Boston Scientific by 89.4% during the first quarter. Essex Financial Services Inc. now owns 4,859 shares of the medical equipment provider’s stock valued at $305,000 after buying an additional 2,294 shares during the last quarter. CHICAGO TRUST Co NA lifted its stake in shares of Boston Scientific by 10.1% in the first quarter. CHICAGO TRUST Co NA now owns 32,887 shares of the medical equipment provider’s stock valued at $2,064,000 after buying an additional 3,009 shares during the period. Deltec Asset Management LLC grew its position in Boston Scientific by 31.0% during the first quarter. Deltec Asset Management LLC now owns 55,400 shares of the medical equipment provider’s stock worth $3,476,000 after buying an additional 13,100 shares in the last quarter. USS Investment Management Ltd increased its stake in Boston Scientific by 4.6% during the first quarter. USS Investment Management Ltd now owns 269,031 shares of the medical equipment provider’s stock valued at $16,876,000 after acquiring an additional 11,950 shares during the period. Finally, IFM Investors Pty Ltd increased its stake in Boston Scientific by 2.5% during the first quarter. IFM Investors Pty Ltd now owns 332,339 shares of the medical equipment provider’s stock valued at $20,854,000 after acquiring an additional 8,151 shares during the period. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director Cheryl Pegus bought 1,770 shares of the company’s stock in a transaction that occurred on Wednesday, May 20th. The stock was acquired at an average price of $56.49 per share, for a total transaction of $99,987.30. Following the transaction, the director directly owned 1,770 shares of the company’s stock, valued at $99,987.30. This trade represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director David C. Habiger purchased 2,250 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The shares were purchased at an average cost of $55.92 per share, with a total value of $125,820.00. Following the completion of the acquisition, the director directly owned 13,878 shares in the company, valued at $776,057.76. The trade was a 19.35% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought 9,800 shares of company stock worth $554,012 in the last quarter. 0.34% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages have commented on BSX. Wells Fargo & Company reiterated an “equal weight” rating and issued a $55.00 price objective (down from $75.00) on shares of Boston Scientific in a research report on Thursday, May 28th. The Goldman Sachs Group set a $71.00 price objective on Boston Scientific in a research report on Thursday, May 28th. Raymond James Financial restated an “outperform” rating and issued a $88.00 target price (down from $97.00) on shares of Boston Scientific in a research note on Monday, March 30th. UBS Group reduced their target price on Boston Scientific from $120.00 to $105.00 and set a “buy” rating for the company in a research report on Tuesday, March 17th. Finally, Wall Street Zen lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a report on Saturday, March 28th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $83.36.

Boston Scientific Price Performance

Shares of BSX stock opened at $45.09 on Friday. The stock’s fifty day simple moving average is $51.39 and its 200 day simple moving average is $69.60. Boston Scientific Corporation has a one year low of $42.25 and a one year high of $109.50. The firm has a market cap of $67.01 billion, a price-to-earnings ratio of 18.86, a P/E/G ratio of 0.82 and a beta of 0.58. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.01. The firm had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The business’s revenue for the quarter was up 11.6% compared to the same quarter last year. During the same period in the prior year, the company posted $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, analysts expect that Boston Scientific Corporation will post 3.36 earnings per share for the current fiscal year.

Boston Scientific announced that its board has approved a share buyback program on Monday, May 18th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s board of directors believes its shares are undervalued.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.